The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis

Clinical Microbiology and Infection

Volumn 13, Issue 1, 2007, Pages 33-39

  Burgess, D S ^a,b   Frei, C R ^a,b   Lewis II, J S ^a,b,c   Fiebelkorn, K R ^b   Jorgensen, J H ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breakpoints; Interpretative susceptibility criteria; Monte Carlo simulation; Neisseria meningitidis; Pharmacokinetics pharmaco dynamics; Susceptibility testing

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFAFURAZOLE; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; HUMAN; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; NEISSERIA MENINGITIDIS;

EID: 33845305033     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01617.x     Document Type: Article

References (38)

1. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. Wayne, PA: NCCLS, 2003.
2. Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience. Pediatr Infect Dis J 1996; 15: 967-979.
3. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr 1981; 99: 540-545.
4. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344: 1378-1388.
5. Musher DM. How contagious are common respiratory tract infections? N Engl J Med 2003; 348: 1256-1266.
6. Jorgensen JH, Crawford SA, Fiebelkorn KR. Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. J Clin Microbiol 2005; 43: 3162-3171.
7. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Supplement M100-S15. Wayne, PA: CLSI, 2005.
8. Ebert SC, Leggett J, Vogelman B, Craig WA. Evidence for a slow elimination phase for penicillin G. J Infect Dis 1988; 158: 200-202.
9. Ripa S, Ferrante L, Prenna M. Pharmacokinetics of sulbactam/ampicillin in humans after intravenous and intramuscular injection. Chemotherapy 1990; 36: 185-192.
10. Kemmerich B, Lode H, Belmega G, Jendroschek T, Borner K, Koeppe P. Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother 1983; 23: 429-434.
11. Chiu LM, Menhinick AM, Johnson PW, Amsden GW. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J Antimicrob Chemother 2002; 50: 1075-1079.
12. Dreetz M, Hamacher J, Eller J et al. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother 1996; 40: 105-109.
13. Burke JT, Wargin WA, Sherertz RJ, Sanders KL, Blum MR, Sarubbi FA. Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function. J Pharmacokinet Biopharm 1982; 10: 601-614.
14. Raghuram TC, Krishnaswamy K. Pharmacokinetics of tetracycline in nutritional edema. Chemotherapy 1982; 28: 428-433.
15. Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA. Pharmacokinetics of minocycline in renal failure. Antimicrob Agents Chemother 1975; 8: 532-537.
16. Oie S, Gambertoglio JG, Fleckenstein L. Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing. J Pharmacokinet Biopharm 1982; 10: 157-172.
17. Stevens RC, Laizure SC, Sanders PL, Stein DS. Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers. Antimicrob Agents Chemother 1993; 37: 448-452.
18. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41: 2670-2679.
19. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992; 36: 993-996.
20. Nguyen VX, Nix DE, Gillikin S, Schentag JJ. Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. Antimicrob Agents Chemother 1989; 33: 434-436.
21. Chien S, Rogge M, Gisclon L et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41: 2256-2260.
22. Gilbert DN, Moellering RC, Sande MA. The Sanford guide to antimicrobial therapy. Hyde Park, VT: Antimicrobial Therapy Inc., 2002.
23. Lutsar I, McCracken GH, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27: 1117-1127.
24. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 1999; 13: 595-618.
25. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27: 10-22.
26. Drusano GL. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36: S42-S50.
27. Shultz TR, Tapsall JW, White PA et al. Chloramphenicol-resistant Neisseria meningitidis containing catP isolated in Australia. J Antimicrob Chemother 2003; 52: 856-859.
28. Casado-Flores J, Osona B, Domingo P, Barquet N. Meningococcal meningitis during penicillin therapy for meningococcemia. Clin Infect Dis 1997; 25: 1479.
29. Woods CR, Smith AL, Wasilauskas BL, Campos J, Givner LB. Invasive disease caused by Neisseria meningitidis relatively resistant to penicillin in North Carolina. J Infect Dis 1994; 170: 453-456.
30. Turner PC, Southern KW, Spencer NJ, Pullen H. Treatment failure in meningococcal meningitis. Lancet 1990; 335: 732-733.
31. Saez-Nieto JA, Fontanals D, Garcia de Jalon J et al. Isolation of Neisseria meningitidis strains with increase of penicillin minimal inhibitory concentrations. Epidemiol Infect 1987; 99: 463-469.
32. Galimand M, Gerbaud G, Guibourdenche M, Riou JY, Courvalin P. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med 1998; 339: 868-874.
33. Van Esso D, Fontanals D, Uriz S et al. Neisseria meningitidis strains with decreased susceptibility to penicillin. Pediatr Infect Dis J 1987; 6: 438-439.
34. Rosenstein NE, Perkins BA, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180: 1894-1901.
35. Centers for Disease Control and Prevention. Effect of new susceptibility breakpoints on reporting of resistance in Streptococcus pneumoniae - United States, 2003. MMWR 2004; 53: 152-154.
36. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
37. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
38. Kuti JL, Horowitz S, Nightingale CH, Nicolau DP. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy 2005; 25: 935-941.